Trial Profile

Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19/CD22 chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Hebei Senlang Biotechnology

Most Recent Events

15 Jun 2023 Results (n=25; July 2021 to December 2022) assessing the safety and efficacy of CAR-T therapy in relapsed/refractory lymphoma with malignant serous cavity effusion, presented at the 28th Congress of the European Haematology Association.
17 Jun 2022 Results (N=26) presented at the 27th Congress of the European Haematology Association.
31 Jan 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com